Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%

3 weeks ago 13

Jonathan Ponciano, The Motley Fool

Sun, February 22, 2026 astatine 12:23 PM CST 4 min read

On February 17, 2026, Redmile Group disclosed a bargain of 695,000 shares of Immunome (NASDAQ:IMNM), an estimated $12.20 cardinal commercialized based connected quarterly mean pricing.

According to a February 17, 2026, SEC filing, Redmile Group accrued its presumption successful Immunome (NASDAQ:IMNM) by 695,000 shares during the 4th fourth of 2025. The estimated transaction value, calculated utilizing the quarter’s mean closing price, was astir $12.20 million. The full presumption worth astatine quarter-end grew by $64.01 million, a fig that includes some the caller shares and changes successful Immunome’s banal price.

This bargain enactment lifts the Immunome involvement to 9.05% of Redmile Group, LLC’s 13F assets nether absorption arsenic of December 31, 2025.
Top 5 holdings aft the filing:
- NASDAQ:SRRK: $229.98 cardinal (16.9% of AUM)
- NASDAQ:KRYS: $167.08 cardinal (12.3% of AUM)
- NASDAQ:NRIX: $153.54 cardinal (11.3% of AUM)
- NASDAQ:STOK: $128.04 cardinal (9.4% of AUM)
- NASDAQ:IMNM: $122.83 cardinal (9.0% of AUM)
As of February 17, 2026, Immunome shares were priced astatine $22.69, up a staggering 120% implicit the past twelvemonth and good outperforming the S&P 500’s astir 13% summation successful the aforesaid period.

Metric

Value

Price (as of marketplace adjacent February 17, 2026)	$22.69
Market capitalization	$2.09 billion
Revenue (TTM)	$9.68 million
Net income (TTM)	($222.74 million)

Immunome develops antibody therapeutics targeting oncology and infectious diseases, with pb programs including IMM-ONC-01 for crab immunotherapy and IMM-BCP-01 for SARS-CoV-2 treatment.
The institution operates a research-driven biopharmaceutical concern model.
It focuses connected leveraging proprietary find platforms to code unmet aesculapian needs successful analyzable illness areas.

Immunome is simply a clinical-stage biotechnology institution focused connected discovering and processing caller antibody-based therapies for oncology and infectious diseases. The company’s competitory vantage lies successful its differentiated pipeline and expertise successful antibody engineering for analyzable illness targets.

Immunome is nary longer conscionable a clinical-stage story. In December, the institution priced a 18.6 cardinal stock offering astatine $21.50, raising astir $400 cardinal successful gross proceeds to money its oncology pipeline. Around the aforesaid time, it reported affirmative Phase 3 RINGSIDE results for varegacestat successful desmoid tumors, cutting the hazard of progression oregon decease by 84% versus placebo and posting a 56% effect rate. A New Drug Application is planned for the 2nd 4th of 2026.

Against that backdrop, adding shares aft a 120% one-year summation signals content that this is not conscionable a momentum commercialized but a pipeline level story. The presumption present represents much than 9% of assets, alongside different concentrated biotech bets.

Long-term investors should recognize what this is. It is simply a capital-intensive, binary-risk business, but 1 present backed by caller currency and late-stage data. If varegacestat moves toward approval, the valuation statement shifts from probability to commercialization. That is simply a antithetic speech entirely.

Read Entire Article